Novartis seeks to move Pluvicto to earlier prostate cancer, but data underwhelm

Lei Lei Wu

News Reporter

BERLIN — Novartis’ Pluvicto cut the risk of prostate cancer progression or death by 28% when added to hormone therapy, and the radiopharmaceutical also slowed progression …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Novartis seeks to move Pluvicto to earlier prostate cancer, but data underwhelm

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Moderna’s CMV vaccine fails Phase 3 study, ending long-shot prevention effort

Frequent flyers: Top drugmakers’ private jets descended on DC more than 120 times this year, data show

Exclusive: China biotech raises $44M to advance in vivo CAR-T programs after early clinical data

Alkermes to acquire Avadel and its narcolepsy drug for up to $2.1B

Takeda makes major bispecific, ADC pact with Innovent for $1.2B upfront

The advent of digital therapeutics and what it means for healthcare

No­var­tis seeks to move Plu­vic­to to ear­li­er prostate can­cer, but da­ta un­der­whelm

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Mod­er­na’s CMV vac­cine fails Phase 3 study, end­ing long-shot pre­ven­tion ef­fort

Fre­quent fly­ers: Top drug­mak­ers’ pri­vate jets de­scend­ed on DC more than 120 times this year, da­ta show

Ex­clu­sive: Chi­na biotech rais­es $44M to ad­vance in vi­vo CAR-T pro­grams af­ter ear­ly clin­i­cal da­ta

Alk­er­mes to ac­quire Avadel and its nar­colep­sy drug for up to $2.1B

Take­da makes ma­jor bis­pe­cif­ic, ADC pact with In­novent for $1.2B up­front

The ad­vent of dig­i­tal ther­a­peu­tics and what it means for health­care

Novartis seeks to move Pluvicto to earlier prostate cancer, but data underwhelm

Moderna’s CMV vaccine fails Phase 3 study, ending long-shot prevention effort

Frequent flyers: Top drugmakers’ private jets descended on DC more than 120 times this year, data show

Exclusive: China biotech raises $44M to advance in vivo CAR-T programs after early clinical data

Alkermes to acquire Avadel and its narcolepsy drug for up to $2.1B

Takeda makes major bispecific, ADC pact with Innovent for $1.2B upfront

The advent of digital therapeutics and what it means for healthcare